Abstract
The signaling/oncogenic activity of beta-catenin can be repressed by the activation of nuclear receptors such as the vitamin A, vitamin D, and androgen receptors. Although these receptors directly interact with beta-catenin and can sequester it away from its transcription factor partner T-cell factor, it is not known if this is the mechanism of trans-repression. Using several different promoter constructs and nuclear receptors and mammalian two-hybrid and mutation analyses we now show that interaction with the co-activator, p300, underlies the trans-repression of beta-catenin signaling by nuclear receptors and their ligands.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Blotting, Western
-
Cell Line, Tumor
-
Cell Nucleus / metabolism*
-
Colonic Neoplasms / metabolism
-
Cyclin D1 / genetics
-
Cytoskeletal Proteins / chemistry
-
Cytoskeletal Proteins / metabolism*
-
DNA Mutational Analysis
-
Electrophoresis, Polyacrylamide Gel
-
Genes, Reporter
-
Genetic Vectors
-
Humans
-
Ligands
-
Luciferases / metabolism
-
Nuclear Proteins / metabolism
-
Plasmids / metabolism
-
Promoter Regions, Genetic
-
Protein Binding
-
Signal Transduction
-
Trans-Activators / chemistry
-
Trans-Activators / metabolism*
-
Transcription Factor AP-1 / metabolism
-
Transcriptional Activation
-
Transfection
-
Tretinoin / metabolism
-
Two-Hybrid System Techniques
-
beta Catenin
Substances
-
CTNNB1 protein, human
-
Cytoskeletal Proteins
-
Ligands
-
Nuclear Proteins
-
Trans-Activators
-
Transcription Factor AP-1
-
beta Catenin
-
Cyclin D1
-
Tretinoin
-
Luciferases